AI Documentation in Pharmaceutical Validation

Weseem Abdullah

1 Introduction

Artificial intelligence (AI) and machine learning (ML) are poised to revolutionize the pharmaceutical industry by enhancing the accuracy and efficiency of validation processes. The U.S. Food and Drug Administration (FDA) is proactively shaping the regulatory landscape to support the integration of AI, establishing clear guidelines and fostering collaborative frameworks. This paper explores how AI-driven documentation generators can revolutionize pharmaceutical validation, aligning with FDA regulations to improve product safety and effectiveness. It specifically focuses on process validation, confirming that manufacturers' outputs consistently meet the predetermined specifications set by their standard operating procedures (SOPs). Additionally, the paper will examine case studies of AI integration within the medical industry to demonstrate how these innovations could shape future regulatory frameworks. Lastly, it will offer best practices for aligning AI tools with FDA compliance, emphasizing the importance of adopting technology in a manner that safeguards patient interests, enhances efficiency, and reduces human error.

2 Current State of Validation

Pharmaceutical validation, a key section of quality assurance (QA), is a critical regulatory requirement that ensures that all drug production and manufacturing processes operate within predefined parameters stipulated by companies own SOPs and FDA regulation. This process is essential not only for regulatory compliance but also for safeguarding patient health. Traditionally, validation involves a series of rigorous testing and documentation processes as seen in figure one. Validation requires significant manual effort in both testing and documentation, which can introduce human errors. Deviations refer to instances where processes do not comply with the predefined standards. Good Documentation Practice (GDP) is utilized for meticulous record-keeping of all the aspects of the manufacturing process. GDP is essential for providing a timeline of credentialed tracking of deviations to ensure proper accountability. Investigations into deviations cost around 25,000 to 50,000 dollars according to CAI, an international automation and validation company. Moreover, the complexity of validating sophisticated drug products in competitive markets often leads to quality assurance being put aside to expedite releases. While haste is not the answer, there is an imperative need to address these concerns with the advent of AI to both ensure patient safety and company profits.



Figure 1

3 Regulatory Framework for AI

The regulatory framework for AI in pharmaceuticals is rapidly evolving to accommodate the unique challenges posed by AI and ML technologies. As the FDA recognizes the potential of these technologies to transform drug development and manufacturing, it has begun to outline collaborative frameworks to ensure safe and effective integration into the pharmaceutical sector. The FDA's approach includes fostering public-private partnerships and engaging with global regulatory counterparts to harmonize standards and practices.

The FDA's emphasis on Good Machine Learning Practice (GMLP) is a cornerstone of the regulatory framework for AI in pharmaceuticals. GMLP encompasses comprehensive practices such as data management, model training, tuning, and validation to ensure AI systems' reliability and safety. This involves detailed guidelines on data management, feature extraction, model training, and interpretability, all crucial for ensuring the reliability and safety of AI-driven systems. Additionally, the FDA's action plans suggest a lifecycle approach to AI regulation as seen in figure 2, stressing the importance of continuous monitoring and adaptation of AI systems from premarket safety assurance to post-market performance monitoring. The diagram displays how to implement the Total Product Lifetime Cycle (TPLC) to the regulation of AI. This requires clear expectations via industry standard SOPS, and transparency to users and the FDA.

Moreover, the agency has proposed a "Predetermined Change Control Plan," which includes SaMD Pre-Specifications (SPS) and Algorithm Change Protocol (ACP) for managing updates and modifications in AI software. This approach ensures that AI technologies remain safe and effective as they evolve post-deployment. The FDA's commitment is also evident in its support for demonstration projects that explore the real-world applications of AI in medical devices, focusing on mitigating bias and improving health equity.



Figure 2

4 Case Studies

While there is no companies creating documentation through AI generation; there are numerous examples of it being utilized in the medical industry:

1. Breast Cancer Screening: AI algorithms have significantly improved the accuracy of breast cancer screening by analyzing mammograms to detect early signs of cancer. These algorithms are trained on large datasets of labeled images, allowing them to identify subtle abnormalities that might be missed by human eyes. This application not only enhances diagnostic accuracy but also potentially leads to earlier interventions and improved patient outcomes.

2. Stroke Diagnosis: In the field of neurology, AI is being used to analyze CT scans for quick and accurate differentiation of stroke types. This rapid analysis enables faster and more targeted treatment options, minimizing the potential for extensive brain damage and improving recovery prospects for patients.

3. Enhancing MRI Quality: Researchers at Harvard Medical School have developed an AI-driven technique called SynthSR that transforms low-resolution clinical MRI scans into high-resolution images suitable for research purposes. This innovation allows for the inclusion of diverse patient data in neuro-imaging studies, potentially broadening our understanding of neurological conditions and improving diagnostic capabilities in settings where only basic MRI technology is available.

4. Predicting Cancer Spread: At King's College London, an AI model has been developed to predict the likelihood of cancer spreading in patients with triple-negative breast cancer. This model, trained on thousands of lymph node images and clinical data, helps in making informed treatment decisions, potentially leading to more personalized and effective patient care strategies.

These case studies represent the forefront applications of AI in medical devices, serving as benchmarks for navigating the rigorous FDA regulatory framework. Each case exemplifies how innovative AI applications are being integrated within the constraints of safety and effectiveness standards set by the FDA. For instance, the AI-driven breast cancer screening tool and the SynthSR technique from Harvard Medical School have both undergone extensive validation to meet FDA's safety and efficacy criteria, showcasing the practical application of the FDA's guidelines in real-world medical diagnostics. Moreover, these case studies highlight the FDA's emphasis on continuous monitoring and real-time data utilization, key components of the proposed TPLC approach. This approach ensures that AI applications in medical devices not only start strong but continue to operate within FDA standards, adapting to new data and clinical environments.

The lessons of GMLP being utilized in the real world medical procedure directly relate to how validation engineers can utilize the guidance protocols to develop algorithmic protocol to reduce human error, and increase efficiency. The British Medical Journey noted that AI systems were able to detect breast cancer from images with an accuracy of 87 percent barely beating doctors who were 86.2 percent accurate. While it is not a significant increase in accuracy, if the algorithm is fine tuned with more images than it could become even diagnostically relevant. Furthermore, this can save valuable human time and resources. Though, this paper is not advocating for replacing esteemed medical professionals with AI, but collaborate to achieve more efficient, effective patient care.

Within the validation field, deviations caused by human error is costly and causes companies to neglect proper validation protocol. Though the partnership with AI, document generation of SOPS and other validation documents can save valuable time and resources. The goal is to leverage AI's speed with human safeguards to streamline creations of such documents.

5 Best Practices and Future

Aligning AI tools with FDA compliance in the pharmaceutical sector is pivotal for ensuring that the integration of these advanced technologies adheres to rigorous safety standards, thereby safeguarding patient interests. This involves adhering to a set of best practices that not only meet regulatory requirements but also enhance operational efficiencies and reduce the potential for human error.

Implementing Robust Validation Processes: Validation is a critical component of FDA compliance; even tools for validation need validation. For AI tools, this means ensuring that the models are trained on high-quality, diverse datasets of digitalized SOPS. It also involves rigorous testing to verify that the AI performs as intended across various real-world scenarios. Additionally, continuous monitoring and updating of AI systems are necessary to address any deviations from expected performance, which should be promptly reported to the FDA as per post-market surveillance requirements.

Documentation and Transparency: Maintaining detailed documentation is crucial. This includes clear records of the AI development process, training data sources, model changes, and performance metrics. Transparency in how the AI model makes decisions is also important, particularly for models used in diagnostic processes. This not only helps in FDA submissions but is essential for gaining trust among healthcare providers and patients.

Educating and Training Staff: Ensuring that staff are well-educated about the AI tools and their regulatory aspects is key. This involves regular training sessions on the operational, ethical, and regulatory dimensions of using AI in pharmaceutical settings. Understanding the boundaries of AI applications and the importance of maintaining human oversight where necessary is crucial for compliance and safety.

Risk Management: Implementing a comprehensive risk management strategy for AI applications is mandatory. This includes assessing potential risks associated with AI-driven decisions, such as biases in AI algorithms that could lead to deviations. Mitigation strategies should be developed to address identified risks, and ongoing risk assessments should be conducted as part of a continuous quality assurance process.

These best practices are essential to implement once document generation technology goes through the rigors of FDA guidance regulations. While feasible now, there are no particular FDA rules on documentation generation yet. Though, the conversation has already begun on how to ensure that QA is not diminished by offloading human attention from it in favor of AI. This sector of the pharmaceutical industry has always been a late adopter to technology. This trend can be attributed to the critical nature of QA processes, which demand high levels of accuracy, reliability, and regulatory compliance. The hesitation to adopt AI and automation in QA processes stems from concerns about validation, the interpretability of AI decisions, and the risk of non-compliance with stringent regulatory standards. However, as AI and machine learning technologies continue to mature and demonstrate their reliability and compliance capabilities, it's likely that their adoption within QA processes will accelerate. As long as the industry continues their best practices of GDP alongside the increased efficiency of AI, deviations caused by human error documentation mistakes may become a thing of the past.

6 Conclusions

AI's introduction into healthcare should not only focus on overcoming technological barriers but also on enhancing human capabilities. Document generation will become a powerful tool for validation. Human error caused deviations is a costly and, now evermore, a preventable issue that can be reduced through AI and ML. While we have not yet reached the early adoption stage for document generation in validation, AI is displaying its capabilities in the medical industry. The case studies exemplifies that the integration of AI should be collaborative effort where technology complements human expertise, rather than replacing it. This partnership can streamline the meticulousness of process validation where engineers become bogged down by the repetitive nature of creating reams of SOPs that differ from one another slightly. The key to adopting AI is to collaboration of another sort, between the public sector and the private. The FDA should listen to the concerns of pharmaceutical companies, but it should draw a firm line in favor of patient safety over company profits. Engaging in early dialogues with the FDA will be a proactive approach for smoother regulatory adherence. This process must be transparent with open records of the AI development process and data sources. While AI document generation in validation still has not reached the early adoption phases, it is fast approaching. This generation of validation engineers will be the ones who will raise AI; the next one may be raised by it.

7 For Further Research

1. “Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan .” FDA, Jan. 2021, www.fda.gov/media/145022/download.

2. “Artificial Intelligence and Medical Products.” FDA, Mar. 2024, www.fda.gov/media/177030/dow

3. Medical Technology. “Home: Ireland – the Jewel in the Life Sciences Crown? - Medical Technology: Issue 75: June 2024.” Home | Ireland – the Jewel in the Life Sciences Crown? - Medical Technology | Issue 75 | June 2024, 4 June 2024

4. “Proposed Regulatory Framework for Modifications to Artificial Intelligence.” FDA, 2022, www.fda.gov/media/122535/download.